Obesity: Pathophysiology and Management.
Obesity: Pathophysiology and Management.
复制标题
DOI:
10.1016/j.jacc.2017.11.011
复制
发表时间:
2018-01-02
影响因子:
24
通讯作者:
Heymsfield SB
中科院分区:
文献类型:
--
作者:
Gadde KM;Martin CK;Berthoud HR;Heymsfield SB
Obesity continues be among the top health concerns across the globe. Despite our failure to contain the high prevalence of obesity, we now have a better understanding of its pathophysiology, and how excess adiposity leads to type 2 diabetes, hypertension, and cardiovascular disease. Lifestyle modification is recommended as the cornerstone of obesity management, but many patients do not achieve long-lasting benefits due to difficulty with adherence as well as physiological and neurohormonal adaptation of the body in response to weight loss. Fortunately, five drug therapies – orlistat, lorcaserin, liraglutide, phentermine/topiramate, and naltrexone/bupropion are available for long-term weight management. Additionally, several medical devices are available for short-term and long-term use. Bariatric surgery yields substantial and sustained weight loss with resolution of type 2 diabetes, although due to high cost and a small risk of serious complications, it is recommended for patients with severe obesity. Benefit-to-risk balance should guide treatment decisions.
登录
查看更多内容
影响因子:
6.9
作者:
Bergman, Richard N.;Stefanovski, Darko;Buchanan, Thomas A.;Sumner, Anne E.;Reynolds, James C.;Sebring, Nancy G.;Xiang, Anny H.;Watanabe, Richard M.
通讯作者:
Watanabe, Richard M.
影响因子:
6.3
作者:
Dhana, Klodian;Kavousi, Maryam;Franco, Oscar H.
通讯作者:
Franco, Oscar H.
影响因子:
3.6
作者:
Breton, Emily R.;Fuemmeler, Bernard F.;Abroms, Lorien C.
通讯作者:
Abroms, Lorien C.
影响因子:
5.4
作者:
Angulo MA;Butler MG;Cataletto ME
通讯作者:
Cataletto ME
影响因子:
6.9
作者:
Aronne, Louis J.;Wadden, Thomas A.;Gadde, Kishore M.
通讯作者:
Gadde, Kishore M.